部局　大学院医学研究科

講座　内科学講座　糖尿病・内分泌・総合内科学分野　糖尿病・内分泌内科学部門

氏名（ふりがな）　淺原　俊一郎（あさはら　しゅんいちろう）

国籍　日本

学歴	年	月	日	事項
1992年	4月	1日		神戸大学医学部入学
1998年	3月	31日		神戸大学医学部卒業
2002年	4月	1日		神戸大学大学院医学系研究科入学
2009年	3月	25日		神戸大学大学院医学系研究科（博士課程）修了 （糖尿病・代謝・内分泌内科学）

学位	年	月	日	事項
2009年	3月	25日		博士(医学)（神戸大学）

免許	年	月	日	事項
1998年	5月	12日		医師免許証

認定医等	年	月	日	事項
2009年	9月	11日		日本内科学会認定内科医
2019年	12月	17日		日本内科学会総合内科専門医
2020年	12月	6日		日本糖尿病学会専門医
2023年	4月	1日		日本内分泌学会専門医
2023年	4月	1日		日本内分泌学会指導医
2023年	8月	2日		内分泌代謝・糖尿病内科領域　専門研修指導医
2023年	12月	10日		日本糖尿病学会指導医

職歴	年	月	日	事項
1998年	6月	1日		神戸大学医学部附属病院　内科研修医
1999年	6月	1日		加古川市民病院（現加古川中央市民病院）　内科研修医
2001年	6月	1日		西脇市立西脇病院　内科医師
2009年	4月	1日		城陽江尻病院　内科医師
2010年	4月	1日		神戸少年鑑別所医務課診療所　内科医長
2016年	4月	1日		城陽江尻病院　内科医師
2016年	9月	1日		神戸大学大学院医学研究科糖尿病・内分泌内科学　特命助教
2018年	8月	1日		神戸大学大学院医学研究科健康創造推進学分野　特命助教
2020年	4月	1日		神戸大学医学部附属病院糖尿病・内分泌内科　助教・診療科長補佐
2021年	7月	1日		Columbia University Irving Medical Center, Research Fellow
2022年	1月	1日		神戸大学医学部附属病院糖尿病・内分泌内科　助教・診療科長補佐
2024年	4月	1日		神戸大学医学部附属病院糖尿病・内分泌内科　病院講師

賞罰

2008年	7月	第45回日本臨床分子医学会学術集会　学術奨励賞
2010年	12月	第22回分子糖尿病学シンポジウム　研究奨励賞
2012年	2月	第26回日本糖尿病・肥満動物学会年次学術集会　若手研究奨励賞
2013年	10月	JADEC International Research Promotion Award
2016年	11月	第5回万有医学奨励賞

業　績　目　録

１．著書　　№.　1

（英文：番号，著者名（掲載順に全員），著書名，発行所，発行年（西暦），頁の順に記入してください。）

（和文：番号，著書名，著者名（掲載順に全員），発行所，頁，発行年（西暦）の順に記入してください。）

（英文）

該当なし

（和文）

1. 糖尿病学 2016「Kcnq1 遺伝子領域による膵β細胞量調節機構」　淺原俊一郎、木戸良明（門脇孝編）診断と治療社、19-27、2016

2. 内分泌疾患・糖尿病・代謝疾患－診療のエッセンス　淺原俊一郎　（横手幸太郎監修）　日本医師会雑誌、243-246、2021

業　績　目　録

２．論文（原著）　　№. 2

（英文：番号，著者名（掲載順に全員），論文題目，発行雑誌名，発行年（西暦），巻，頁，（IF=　，CI=　）の順に記入してください。　corresponding author(s)には，著者名の左に＊を付してください。）

（和文：番号，論文題目，著者名（掲載順に全員），発行雑誌名，巻，頁，発行年（西暦）の順に記入してください。）　［ 総説，その他も同様（IF，CI は不要）］

（英文）

1. Asahara S, ＊Saigo K, Hasuike N, Tamura M, Maeda Y, Tomofuji Y, Chinzei T, Tatsumi E. Acute lymphoblastic leukemia accompanied by chromosomal abnormality of translocation (12;17). Haematologia (Budap) 2001 31(3):209-213 （IF=N/A, CI= 13）

2. Tsuji G, Maekawa S, ＊Saigo K, Nobuhara Y, Nakamura T, Kawano S, Koshiba M, Asahara S, Chinzei T, Kumagai S. Dermatomyositis and myelodysplastic syndrome with myelofibrosis responding to methotrexate therapy. Am J Hematol. 2003 74(3):175-178（IF= 10.1, CI= 15）

③ Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, Takeda A, Tsuchihashi D, Nishizawa A, Ogawa W, Fujimoto Y, Okamura H, Arden KC, Herrera PL, Noda T, ＊Kasuga M. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat Genet. 2006 38:589-593 （IF= 31.8, CI= 186）

④ Shigeyama Y, Kobayashi T, ＊Kido Y, Hashimoto N, Asahara S, Matsuda T, Takeda A, Inoue T, Shibutani Y, Koyanagi M, Uchida T, Inoue M, Hino O, Kasuga M, Noda T. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Mol Cell Biol. 2008 28:2971-2979 （IF= 3.2, CI= 147）

5. Inoue T, ＊Kido Y, Asahara S, Matsuda T, Shibutani Y, Koyanagi M, Kasuga M. Effect of intrauterine undernutrition during late gestation on pancreatic β cell mass. Biomed. Res. 2009 30:325-330 （IF= 1.3, CI= 21）

6. Asahara S, Matsuda T, ＊Kido Y, Kasuga M. Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes. Biochem Biophys Res Commun. 2009 381:367-371 （IF= 2.5, CI= 16）

⑦ Matsuda T., Kido Y., Asahara S., Kaisho T., Tanaka T., Hashimoto N., Shigeyama Y., Takeda A., Inoue T., Shibutani Y., Koyanagi M., Hosooka T., Matsumoto M., Inoue H., Uchida T., Koike M., Uchiyama Y., Akira S., ＊Kasuga M. Ablation of C/EBPβ alleviates ER stress and pancreatic β cell failure through the GRP78 chaperone in mice. J. Clin. Invest. 2010 120: 115-126 （IF= 13.3, CI= 84）

8. Koyanagi M., Asahara S., Matsuda T., Hashimoto N., Shigeyama Y., Shibutani Y., Kanno A., Fuchita M., Mikami T., Hosooka T., Inoue H., Matsumoto M., Koike M., Uchiyama Y., Noda T., Seino S., Kasuga M., ＊Kido Y. Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. PLoS ONE 2011 6: e23238 （IF= 2.9, CI= 51）

9. Shimizu S., Hosooka T., Matsuda T., Asahara S., Koyanagi-Kimura M., Kanno A.,

Bartolome A., Etoh H., Fuchita M., Teruyama K., Takahashi H., Inoue H., Mieda Y., Hashimoto N., Seino S., ＊Kido Y. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPβ transgenic mice. J. Mol. Endcrinol. 2012 49: 125-135 （IF= 3.6, CI= 39）

10. Kimura K, Yamada T, Matsumoto M, Kido Y, Hosooka T, Asahara S, Matsuda T, Ota T, Watanabe H, Sai Y, Miyamoto K, Kaneko S, Kasuga M, ＊Inoue H. Endoplasmic reticulum stress inhibits STAT3-dependent suppression of hepatic gluconeogenesis via dephosphorylation and deacetylation. Diabetes. 2012 61:61-73 （IF= 6.2, CI= 70）

11. Asahara S, Shibutani Y, Teruyama K, Inoue H, Kawada Y, Etoh H, Matsuda T, Kimura-Koyanagi M, Hashimoto N, Sakahara M, Fujimoto W, Takahashi H, Ueda S, Hosooka T, Satoh T, Inoue H, Matsumoto M, Aiba A, Kasuga M, ＊Kido Y. Ras-related C3 botulinum toxin substrate 1 (RAC1) regulates glucose-stimulated insulin secretion via modulation of F-actin. Diabetologia 2013 56:1088-1097 （IF= 8.4, CI= 75）

12. Shibutani Y, Asahara S, Teruyama K, Inoue H, Matsuda T, Seino S, ＊Kido Y. Constitutive activation of Rac1 in pancreatic β cells facilitates F-actin depolymerization but exerts no influence on the increase of pancreatic β cell mass and facilitation of insulin secretion. Kobe J Med Sci 2013 59:72-80 （IF= N/A, CI=N/A）

13. Kimura K, Nakamura Y, Inaba Y, Matsumoto M, Kido Y, Asahara S, Matsuda T, Watanabe H, Maeda A, Inagaki F, Mukai C, Takeda K, Akira S, Ota T, Nakabayashi H, Kaneko S, Kasuga M, ＊Inoue H. Histidine augments the suppression of hepatic glucose production by central insulin action. Diabetes 2013 62: 2266-2277 （IF= 6.2, CI= 58）

14. Yoshida Y, Fuchita M, Kimura-Koyanagi M, Kanno A, Matsuda T, Asahara S, Hashimoto N, Isagawa T, Ogawa W, Aburatani H, Noda T, Seino S, Kasuga M, ＊Kido Y. Contribution of insulin signaling to the regulation of pancreatic beta-cell mass during the catch-up growth period in a low birth weight mouse model. Diabetol Int. 2014 5:43-52 （IF= 1.3, CI=N/A）

15. Bartolomé A, Kimura-Koyanagi M, Asahara S, Guillén C, Inoue H, Teruyama K, Shimizu S, Kanno A, García-Aguilar A, Koike M, Uchiyama Y, Benito M, Noda T, ＊Kido Y. Pancreatic β cell failure mediated by mTORC1 hyperactivity and autophagic impairment. Diabetes 2014 63:2996-3008 （IF= 6.2, CI= 104）

16. Kanno A, Asahara S, Masuda K, Matsuda T, Kimura-Koyanagi M, Seino S, Ogawa W, ＊Kido Y. Compensatory hyperinsulinemia in high-fat diet-induced obese mice is associated with enhanced insulin translation in islets. Biochem Biophys Res Commun. 2015 458 : 681-686 （IF= 2.5, CI= 21）

17. Matsuda T, Takahashi H, Mieda Y, Shimizu S, Kawamoto T, Matsuura Y, Takai T, Suzuki E, Koyanagi-Kimura M, Asahara S, Bartolome A, Yokoi N, Inoue H, Ogawa W, Seino S, ＊Kido Y. Regulation of pancreatic β cell mass by cross-interaction between CCAAT enhancer binding protein β induced by endoplasmic reticulum stress and AMP-activated protein kinase activity. PLoS ONE. 2015 10:e0130757 （IF= 2.9, CI= 16）

18. Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, Kawada Y, Bartolome A, Hashimoto N, Matsuda T, Koyanagi-Kimura M, Kanno A, Hirota Y, Hosooka T, Nagashima K, Nishimura W, Inoue H, Matumoto M, Higgins MJ, Yasuda K, Inagaki N, Seino S, Kasuga

M, ＊Kido Y. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β cell mass via epigenetic modification of Cdkn1c. Proc Natl Acad Sci USA. 2015 112(27):8332-8337 （IF= 9.4, CI= 48）

19. Kimura K, Tanida M, Nagata N, Inaba Y, Watanabe H, Nagashimada M, Ota T, Asahara S, Kido Y, Matsumoto M, Toshinai K, Nakazato M, Shibamoto T, Kaneko S, Kasuga M, ＊Inoue H. Centra insulin-action activates Kupffer cells by suppressing hepatic vagal activation through nicotinic alpha 7 acetylcholine receptor. Cell Rep 2016 14(10):2362-2374 （IF= 7.5, CI= 68）

20. Watanabe H, Inaba Y, Kimura K, Asahara S, Kido Y, Matsumoto M, Motoyama T, Tachibana N, Kaneko S, Kohno M, ＊Inoue H. Dietary mung bean protein reduces hepatic steatosis, fibrosis, and inflammation in male mice with diet-induced, Nonalcoholic Fatty Liver Disease. J Nutr. 2017 147:52-60 （IF= 3.7, CI= 39）

21. Kawada Y, Asahara S, Sugiura Y, Sato A, Furubayashi A, Kawamura M, Bartolome A, Terashi-Suzuki E, Takai T, Kanno A, Koyanagi-Kimura M, Matsuda T, Hashimoto N, ＊Kido Y. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells. PLoS One. 2017 12: e0184435 （IF= 2.9, CI= 20）

22. Bartolomé A, García-Aguilar A, Asahara S, Kido Y, ＊Guillén C, Pajvani UB, Benito M. MTORC1 Regulates both General Autophagy and Mitophagy Induction after Oxidative Phosphorylation Uncoupling. Mol Cell Biol. 2017 37(23) e00441-17 （IF= 3.2, CI= 95）

23. Takai T, Matsuda T, Matsuura Y, Inoue K, Suzuki E, Kanno A, Kimura-Koyanagi M, Asahara S, Hatano N, Ogawa W, ＊Kido Y. Casein kinase 2 phosphorylates and stabilizes C/EBPβ in pancreatic β cells. Biochem. Biophys. Res. Commun. 2018 497:451-456 （IF= 2.5, CI= 5）

24. Yano H, Sakai M, Matsukawa T, Yagi T, Naganuma T, Mitsushima M, Iida S, Inaba Y, Inoue H, Unoki-Kubota H, Kaburagi Y, Asahara S, Kido Y, Minami S, Kasuga M, ＊Matsumoto M. PHD3 regulates glucose metabolism by suppressing stress-induced signalling and optimising gluconeogenesis and insulin signalling in hepatocytes. Sci Rep. 2018 8(1):14290. （IF= 3.8, CI= 14）

25. Kanno A, Asahara S, Kawamura M, Furubayashi A, Tsuchiya S, Suzuki E, Takai T, Koyanagi-Kimura M, Matsuda T, Okada Y, Ogawa W, ＊Kido Y. Early administration of dapagliflozin preserves pancreatic β-cell mass through a legacy effect in a mouse model of type 2 diabetes. J Diabetes Investig. 2019 10(3):577-590 （IF= 3.1, CI= 15）

26. Suzuki E, Matsuda T, Kawamoto T, Takahashi H, Mieda Y, Matsuura Y, Takai T, Kanno A, Koyanagi-Kimura M, Asahara S, Inoue H, Ogawa W, ＊Kido Y. Docosahexaenoic acid reduces palmitic acid-induced endoplasmic reticulum stress in pancreatic β cells. Kobe J Med Sci. 2018 64(2):E43-E55. （IF= N/A, CI=N/A）

27. Inoue H, Saito M, Kouchi K, ＊Asahara SI, Nakamura F, Kido Y. Association between mean platelet volume in the pathogenesis of type 2 diabetes mellitus and diabetic macrovascular complications in Japanese patients. J Diabetes Investig. 2020 11(4):938-945 （IF= 3.1, CI= 14）

28. Katsuyama A, ＊Kusuhara S, Asahara SI, Nakai SI, Mori S, Matsumiya W, Miki A, Kurimoto T, Imai H, Kido Y, Ogawa W, Nakamura M. En face slab optical coherence

tomography imaging successfully monitors progressive degenerative changes in the innermost layer of the diabetic retina. BMJ Open Diabetes Res Care. 2020 8(1):e001120 (IF= 3.7, CI= 6)

(29) Kanno A, ＊Asahara SI, Furubayashi A, Masuda K, Yoshitomi R, Suzuki E, Takai T, Kimura-Koyanagi M, Matsuda T, Bartolome A, Hirota Y, Yokoi N, Inaba Y, Inoue H, Matsumoto M, Inoue K, Abe T, Wei FY, Tomizawa K, Ogawa W, Seino S, Kasuga M, ＊Kido Y. GCN2 regulates pancreatic β cell mass by sensing intracellular amino acid levels. JCI Insight. 2020 5(9):e128820 (IF= 6.3, CI= 17)

(30) Asahara SI, Miura H, Ogawa W, ＊Tamori Y. Sex difference in the association of obesity with personal or social background among urban residents in Japan. PLoS One. 2020 15(11):e0242105 (IF= 2.9, CI= 9)

31. Inoue H, ＊Asahara SI, Sugiura Y, Kawada Y, Imai A, Hara C, Kanno A, Kimura-Koyanagi M, Kido Y. Histone deacetylase 6 regulates insulin signaling in pancreatic β cells. Biochem Biophys Res Commun. 2021 534:896-901 (IF= 2.5, CI= 4)

32. Han G, ＊Takahashi H, Murao N, Gheni G, Yokoi N, Hamamoto Y, Asahara SI, Seino Y, Kido Y, ＊Seino S. Glutamate is an essential mediator in glutamine-amplified insulin secretion. J Diabetes Investig. 2021 12(6):920-930 (IF= 3.1, CI= 23)

33. Asakawa T, ＊Onizawa M, Saito C, Hikichi R, Yamada D, Minamidate A, Mochimaru T, Asahara SI, Kido Y, Oshima S, Nagaishi T, Tsuchiya K, Ohira H, Okamoto R, ＊Watanabe M. Oral administration of D-serine prevents the onset and progression of colitis in mice. J Gastroenterol. 2021 56(8):732-745 (IF= 6.9, CI= 12)

34. Inaba Y, Hashiuchi E, Watanabe H, Kimura K, Oshima Y, Tsuchiya K, Murai S, Takahashi C, Matsumoto M, Kitajima S, Yamamoto Y, Honda M, Asahara SI, Ravnskjaer K, Horike SI, Kaneko S, Kasuga M, Nakano H, Harada K, ＊Inoue H. The transcription factor ATF3 switches cell death from apoptosis to necroptosis in hepatic steatosis in male mice. Nat Commun. 2023 14(1):167 (IF= 14.7, CI= 28)

(35) ＊Watanabe H, Du W, Son J, Sui L, Asahara SI, Kurland IJ, Kuo T, Kitamoto T, Miyachi Y, de Cabo R, ＊Accili D. Cyb5r3-based mechanism and reversal of secondary failure to sulfonylurea in diabetes. Sci Transl Med. 2023 15(681):eabp4126 (IF= 15.8, CI= 6)

36. Seike M, ＊Asahara SI, Inoue H, Kudo M, Kanno A, Yokoi A, Suzuki H, Kimura-Koyanagi M, Kido Y, Ogawa W. L-Asparaginase regulates mTORC1 activity via a TSC2-dependent pathway in pancreatic beta cells. Biochem Biophys Res Commun. 2023 652:121-130 (IF= 2.5, CI= 2)

37. ＊Amano S, Suenaga S, Hamamoto K, Yada S, Tsuyama T, Shinoda S, Tanaka Y, Takemoto Y, Harada E, Tanabe K, Asahara S, Hoshii K, Takami T. A case of multiple glucagonomas with no clinical manifestations of excess glucagon despite hyperglucagonemia. DEN Open. 2023 3(1):e230 (IF= 1.4, CI= 1)

38. Ihara Y, ＊Asahara SI, Inoue H, Seike M, Ando M, Kabutoya H, Kimura-Koyanagi M, Kido Y. Chlorogenic acid and caffeine in coffee restore insulin signaling in pancreatic beta cells. Kobe J Med Sci. 2023 69(1):E1-E8. (IF= N/A, CI=N/A)

39. Yamada T, ＊Asahara SI, Kimura-Koyanagi M, Tamori Y, Muramae N, Mori K, Okano M,

Otsui K, Sakaguchi K. Distinct hypoglycemic effect of different formulations of a fixed ratio of basal insulin plus glucagon-like peptide-1 receptor agonist in a patient with pancreatic diabetes. Diabetol Int. 2023 14(3):294-297 (IF= 1.3, CI= 0)

40. Matsukawa T, Yagi T, Uchida T, Sakai M, Mitsushima M, Naganuma T, Yano H, Inaba Y, Inoue H, Yanagida K, Uematsu M, Nakao K, Nakao H, Aiba A, Nagashima Y, Kubota T, Kubota N, Izumida Y, Yahagi N, Unoki-Kubota H, Kaburagi Y, Asahara SI, Kido Y, Shindou H, Itoh M, Ogawa Y, Minami S, Terauchi Y, Tobe K, Ueki K, Kasuga M, ＊Matsumoto M. Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models. JCI Insight. 2023 8(17):e161282 (IF= 6.3, CI= 7)

41. ＊Watanabe H, Asahara SI, Son J, McKimpson WM, de Cabo R, ＊Accili D. Cyb5r3 activation rescues secondary failure to sulfonylurea but not β-cell dedifferentiation. PLoS One. 2024 19(2):e0297555. (IF= 2.9, CI= 2)

42. ＊Mikajiri R, Fukunaga A, Miyoshi M, Maeshige N, Washio K, Masaki T, Nishigori C, Yamamoto I, Toda A, Takahashi M, Asahara SI, Kido Y, Usami M. Dietary intervention for control of clinical symptom in patients with systemic metal allergy: A Single Center Randomized Controlled Clinical Study. Kobe J Med Sci. 2024 69(4):E129-E143. (IF= N/A, CI=N/A)

43. Inoue H, ＊Asahara SI, Nakamura F, Kido Y. A high Fibrosis-4 Index is associated with a reduction in the estimated glomerular filtration rate in non-obese Japanese patients with type 2 diabetes mellitus. Kobe J Med Sci. 2024 70(1):E39-E45. (IF= N/A, CI=N/A)

44. Yokoi A, ＊Asahara SI, Inoue H, Seike M, Kido N, Suzuki H, Kanno A, Kimura-Koyanagi M, Kido Y, Ogawa W. Dapagliflozin administration to a mouse model of type 2 diabetes induces DNA methylation and gene expression changes in pancreatic islets. Biochem Biophys Res Commun. 2024 725:150254. (IF= 2.5, CI= 0)

45. Ueda M, ＊Zenibayashi M, Yamada T, Asahara SI, Ogawa W. Comparison over time of adverse drug reactions in diabetes patients treated with sodium-glucose cotransporter 2 inhibitors. Kobe J Med Sci. 2024 70(3):E81-E88. (IF= N/A, CI=N/A)

46. ＊Takai T, Asahara SI, Ikushiro H, Kobayashi K, Yano T, Kido Y, Ogawa W. Protective effect of CK2 against endoplasmic reticulum stress in pancreatic β cells. Diabetol Int. 2024, in press. (IF= 1.3 , CI= N/A)

47. Amo-Shiinoki K, ＊Tanabe K, Nishimura W, Hatanaka M, Kondo M, Kagawa S, Zou M, Morikawa S, Sato Y, Komatsu M, Mizukami H, Nishida N, Asahara SI, Masutani H, Tanizawa Y. β-cell dedifferentiation, the underlying mechanism of diabetes in Wolfram syndrome. Sci Transl Med. 2024 in press. (IF= 15.8, CI= N/A)

(48) ＊Asahara SI, Inoue HY, Ihara Y, Teruyama K, Imai A, Hara C, Hara M, Seike M, Yokoi A, Kido N, Suzuki H, Kanno A, Inaba Y, Watanabe H, Shioi G, Kimura-Koyanagi M, Matsumoto M, Inoue H, Nakayama KI, Ogawa W, Kasuga M, Kido Y. High-fat diet-fed Kcnq1 mutant mice have reduced pancreatic β-cell mass via gene-environment interaction. Diabetes Metab J. 2025, in press. (IF= 6.8, CI= N/A)

49. Taniguchi A, Watanabe H, Kimura K, Hashiuchi E, Ohashi N, Sato H, Sakai M, Matsumoto M, Asahara SI, Inoue H, ＊Inaba Y. Proline enhances the hepatic induction of lipogenic gene expression in male hepatic Fasn reporter mice. Biochem Biophys Res Commun. 2025

747:151314.（IF= 2.5，CI= N/A）

50. Miyazaki K, Yokoi A, Inoue H, Suzuki H, Kido N, Kanno A, Kimura-Koyanagi M, Kido Y, ＊Asahara SI. The usefulness of HbA1c measurement in diabetic mouse models using various devices. Exp Anim. 2025, in press. （IF= 2.2，CI= N/A）

51. Yokoi A, ＊Asahara SI, Inoue H, Goto A, Seike M, Kido N, Suzuki H, Kanno A, Kimura-Koyanagi M, Uto K, Saegusa J, Kido Y, Ogawa W. MiR378a-3p in serum extracellular vesicles is associated with pancreatic beta-cell mass in diabetic states. Biochem Biophys Res Commun. 2025, in press. （IF= 2.5，CI= N/A）

（和文）

1. All-Trans レチノイン酸併用 Cytosine Arabinoside 少量療法が有効であった Trilineage Myelodiaplasia を伴った急性骨髄性白血病の一例　前田真美、佐竹信哉、岡田裕子、淺原俊一郎、蓮池典明、田村美歩、高田政文、田坂勝視、奥谷俊夫、前田裕一郎、友藤喜信、鎮西忠信、西郷勝康　癌と化学療法 28(3):407-410, 2001

2. メタノール中毒における血液透析の有効性とクリアランス値の検討　高瀬弘行、藤本英亮、笹倉良一、淺原俊一郎、岩井正秀、福永秀行　日本透析医学会雑誌 9:1443-1446, 2003

業　績　目　録

３．論文（総説）　　No. 3

（英文）

1. ＊Asahara S, Inoue H, Kido Y. Regulation of Pancreatic β-Cell Mass by Gene-Environment Interaction. Diabetes Metab J. 2022 46(1):38-48

2. ＊Asahara S, Inoue H, Watanabe H, Kido Y. Roles of mTOR in the Regulation of Pancreatic β-Cell Mass and Insulin Secretion. Biomolecules 2022 12(5):614

（和文）

1. エピジェネティクスと糖尿病　淺原俊一郎、木戸良明　ゲノム医学　9:127-131, 2009

2. 移植直後の膵島細胞と HMGB1　淺原俊一郎、木戸良明　BIO Clinica　27:91-96, 2012

3. 胎内環境と 2 型糖尿病　淺原俊一郎、木戸良明　最新医学　67:93-99, 2012

4. 膵β細胞のインスリン抵抗性　淺原俊一郎、木戸良明　Diabetes Frontier　26: 321-325, 2015

5. 膵β細胞の Kcnq1 遺伝子領域におけるエピジェネティクス制御機構　淺原俊一郎　内分泌・糖尿病・代謝内科　40: 268-274, 2015

6. 膵β細胞量の調節因子　淺原俊一郎、木戸良明　最新医学　70: 487-495, 2015

7. 淺原俊一郎、木戸良明、脇　裕典、山内敏正、門脇　孝　糖尿病とエピジェネティクス　ANTI-AGING MEDICINE　2016　12：6：55-62

8. 淺原俊一郎、木戸良明　アジア人型感受性遺伝子 KCNQ1 欠損マウスを用いた病態解析　Diabetes Frontier　2016　27: 496-501

業　績　目　録

４．論文（その他）　№. 4

（英文）

1. ＊Asahara S, Ogawa W. SGLT2 inhibitors and protection against pancreatic beta cell failure. Diabetol Int. Editorial 2018 10(1):1-2

2. ＊Asahara S. Neuronatin and glucose-induced stress in pancreatic β cells. J Diabetes Investig. Commentary 2019 10(3):574-576

3. ＊Asahara S. Patch-seq shows the heterogeneity of pancreatic islet cells. J Diabetes Investig. Commentary 2021 12(5):691-693

（和文）

該当なし

業　績　目　録

５．学会発表（国内学会）　№. 5

（番号，演題名，発表者（共同発表者を含む），学会名，発行年の順に記入してください。）

シンポジウム

1. 糖尿病発症機転における膵β細胞の細胞周期異常 内田亨，木戸良明，橋本尚子，淺原俊一郎，茂山豊，松田友和，竹田章彦，春日雅人 第 48 回日本糖尿病学会年次学術集会 2005

2. 小胞体ストレスにより惹起される膵β細胞不全における C/EBPβの役割 松田友和，木戸良明，渋谷由紀，井上妙，竹田章彦，茂山豊，淺原俊一郎、内田亨，春日雅人 第 18 回分子糖尿病学シンポジウム 2006

3. 糖尿病発症における膵β細胞量の異常 木戸良明，中野尚子，茂山豊，松田友和，淺原俊一郎，竹田章彦，井上妙，渋谷由紀，内田亨，春日雅人 第 50 回日本糖尿病学会年次学術集会 2007

4. 膵β細胞における低分子量 G タンパク Rac1 の機能解析　淺原俊一郎、木戸良明、松田友和、渋谷由紀、小柳真希、清野　進、春日雅人　第 21 回分子糖尿病学シンポジウム　2009

5. 2 型糖尿病候補遺伝子 KCNQ1 の膵β細胞に及ぼす役割の検討　淺原俊一郎、江藤博昭、照山杏子、小柳真希、渋谷由紀、松田友和、長島一昭、西村　渉、安田和基、清野　進、春日雅人、木戸良明　第 22 回分子糖尿病学シンポジウム　2010

6. Regulation of pancreatic beta cell mass through type 2 diabetes susceptibility genes 淺原俊一郎、木戸良明　第 59 回日本糖尿病学会年次学術集会　2016

7. SGLT2 阻害薬早期導入における有用性～臓器保護の観点を含めて～　淺原俊一郎　第 56 回日本臨床分子医学会学術集会　2019

8. 膵島ホメオスタシスにおいて mTOR が果たす役割の解明　淺原俊一郎　第 65 回日本糖尿病学会年次学術集会　2022

9. 膵β細胞における mTORC1 活性化が膵島可塑性に及ぼす影響の検討　木戸希、淺原俊一郎、清家雅子、椎木幾久子、田部勝也、水上浩哉、木戸良明、小川渉　第 34 回分子糖尿病学シンポジウム　2023

業　績　目　録

６．学会発表（国際会議）　№. 6

（番号，演題名，発表者（共同発表者を含む），学会名，発行年の順に記入してください。）

シンポジウム

1. Accumulation of C/EBPβ induces pancreatic β cell failure by suppressing the induction of GRP78 in the endoplasmic reticulum. Matsuda T, Kido Y, Asahara S, Shigeyama Y, Takeda A, Inoue T, Shibutani Y, Koyanagi M, Uchida T, Kasuga M. The 9th Symposium on Molecular Diabetology in Asia. 2007

2. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass via epigenetic modification of Cdkn1c. Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, Bartolome A, Hashimoto N, Matsuda T, Koyanagi-Kimura M, Kanno A, Nagashima K, Nishimura W, Yasuda K, Inagaki N, Seino S, Kasuga M, Kido Y. Beta Cell Workshop 2013 Kyoto. 2013

3. Pancreatic β-cell failure in Asian patients with type2 diabetes. Asahara S. 3rd Annual Meeting of DDES. 2016

4. Regulation of pancreatic beta cell mass through type 2 diabetes susceptibility genes. Asahara S. AIBIS 2017. 2017

5. GCN2, a type2 diabetes mellitus susceptibility gene, is associated with the regulation of pancreatic beta cell mass. Asahara S. UW・UO・KU The 2nd International Joint Symposium in Honolulu. 2018

6. Role of mTORC1 in the regulation of pancreatic beta cell mass. Asahara S. International Congress of Diabetes and Metabolism. 2023

一般演題

1. Role of TSC2 in the regulation of pancreatic β cell mass. Shigeyama Y, Kido Y, Hashimoto N, Asahara S, Matsuda T, Takeda A, Inoue T, Shibutani Y, Uchida T, Noda T, Kasuga M. 67th Scientific Session of American Diabetes Association. 2007

2. Accumulation of C/EBPβ induces pancreatic β cell failure by reducing the endoplasmic reticulum function. Matsuda T, Kido Y, Hashimoto N, Asahara S, Shigeyama Y, Takeda A, Inoue T, Shibutani Y, Uchida T, Kasuga M. 67th Scientific Session of American Diabetes Association. 2007

3. Rac1 regulates glucose-induced insulin secretion through modulation of cytoskeletal organization in beta cells. Asahara S, Kido Y, Shigeyama Y, Matsuda T, Takeda A, Inoue T, Shibutani Y, Koyanagi M, Uchida T, Kasuga M. 68th Scientific Session of American Diabetes Association 2008

4. Ablation of TSC2 enhances mitochondrial function via activation of mTORC1 in β cells. Koyanagi M, Kido Y, Asahara S, Shigeyama Y, Matsuda T, Shibutani Y, Fuchita M, Noda T, Seino S, Kasuga M. 70th Scientific Session of American Diabetes Association. 2010

5. Effect of intrauterine undernutrition during late gestation on pancreatic beta cell mass. Fuchita M, Koyanagi M, Asahara S, Inoue T, Yoshida Y, Kasuga M, Seino S, Kido Y. 47th EASD Annual Meeting. 2011

6. Effect of DPP-4 inhibitor vildagliptin on pancreatic beta cell failure in beta cell-specific C/EBPβ transgenic mice. Shimizu S, Hosooka T, Matsuda T, Asahara S, Seino S, Kido Y. 47th EASD Annual Meeting. 2011

7. Rac1 Regulates Glucose-stimulated Insulin Secretion via Modulation of F-actin. Asahara S Kick-off Workshop Strategic Japanese-Danish Cooperative program on Molecular Diabetology 2011

8. Reduction in pancreatic beta cell mass caused by enhanced expression of Cdkn1c as a result of interaction between C/EBPβ and epigenetic control. Teruyama K, Asahara S, Inoue H, Etoh H, Matsuda T, Seino S, Kido Y. 48th EASD Annual Meeting. 2012

9. Pancreatic beta cell failure mediated by mTORC1 hyperactivity and autophagic impairment. Bartolome A, Kimura-Koyanagi M, Shimizu S, Kanno A, Guillen C, Benito M, Asahara S, Kido Y. 48th EASD Annual Meeting. 2012

10. Protective effect of DPP-4 inhibitor Vildagliptin on pancreatic beta-cells in beta-cell specific C/EBPbeta transgenic mice. Matsuda T, Takahashi H, Mieda Y, Asahara S, Kanno A, Koyanagi M, Seino S, Kido Y. 9th IDF/4th AASD. 2012

11. Reduction in pancreatic beta-cell mass by enhanced expression of Cdkn1c as a result of interaction between C/EBPbeta and epigenetic control. Asahara S, Teruyama K, Etoh H, Inoue H, Ihara Y, Kawada Y, Matsuda T, Yasuda K, Kasuga M, Seino S, Kido Y. 9th IDF/4th AASD. 2012

12. GCN2, a type 2 diabetes mellitus susceptibility gene, is associated with the regulation of pancreatic β-cell mass. Kanno A, Yoshitomi R, Asahara S, Matsuda T, Koyanagi M, Shibutani Y, Yokoi N, Kasuga M, Seino S, Kido Y. Beta Cell Workshop 2013 Kyoto. 2013

13. Modulation of C/EBPβ expression via AMPK regulates pancreatic β-cell mass. Matsuda T, Takahashi H, Mieda Y, Asahara S, Kanno A, Koyanagi M, Seino S, Kido Y. Beta Cell Workshop 2013 Kyoto. 2013

14. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic beta cell mass via epigenetic modification of Cdkn1c. Inoue. H, Asahara S, Etoh H, Teruyama K, Ihara Y, Matsuda T, Koyanagi-Kimura M, Kanno A, Nagashima K, Nishimura W, Yasuda K, Inagaki N, Seino S, Kasuga M, Kido Y. 49th EASD Annual Meeting. 2013

15. Modulation of C/EBP beta expression via AMPK regulates pancreatic beta cell mass. Takahashi H, Matsuda T, Mieda Y, Asahara S, Terashi E, Kanno A, Koyanagi M, Bartolome A, Seino S, Kido Y. 49th EASD Annual Meeting. 2013

16. Paternal allelic mutation at the Kcnq1 locus reduces pancreatic β-cell mass via epigenetic modification of Cdkn1c. Asahara S, Etoh H, Inoue H, Teruyama K, Shibutani Y, Ihara Y, Bartolome A, Hashimoto N, Matsuda T, Koyanagi-Kimura M, Kanno A, Nagashima K, Nishimura W, Yasuda K, Inagaki N, Seino S, Kasuga M, Kido Y. The Scientific Program Committee of ICDM2013 and 5th AASD Scientific Meeting. 2013

17. Modulation of C/EBPβ expression via AMPK regulates pancreatic β-cell mass. Matsuda T, Takahashi H, Mieda Y, Kawamoto T, Terashi E, Kanno A, Kimura-Koyanagi M, Asahara S, Kido Y. The Scientific Program Committee of ICDM2013 and 5th AASD Scientific Meeting. 2013

18. Reduction in pancreatic β-cell mass caused by enhanced expression of Cdkn1c via interaction between C/EBPβ and epigenetic control. Ihara Y, Asahara S, Inoue H, Teruyama K, Matsuda T, Seino S, Kido Y. 50th EASD Annual Meeting. 2014

19. Cross-interaction between C/EBPβ and AMPK determines the pancreatic β-cell mass. Mieda Y, Takahashi H, Matsuda T, Asahara S, Terashi E, Kanno A, Koyanagi M, Seino S, Kido Y. 50th EASD Annual Meeting. 2014

20. Reduction in Pancreatic β-Cell Mass Caused by Enhanced Expression of Cdkn1c via Interaction between C/EBPβ and Epigenetic Control. Asahara S, Ihara Y, Inoue H, Teruyama K, Hara M, Kimura M, Matsuda T, Seino S, Kido Y. 75th Scientific Session of American Diabetes Association. 2015

21. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells Sugiura Y, Asahara S, Kawada Y, Ihara Y, Hara M, Kanno A, Kimura-Koyanagi M, Matsuda T, Seino S, Ogawa W, Kido Y. 7th AASD Scientific Meeting. 2015

22. GCN2, a type 2 diabetes mellitus susceptibility gene, is associated with the regulation of pancreatic β-cell mass. Masuda K, Kanno A, Yoshitomi R, Asahara S, Matsuda T, Kimura M, Shibutani Y, Yokoi N, Kasuga M, Seino S, Kido Y. 51st EASD Annual Meeting. 2015

23. GCN2, a type 2 diabetes mellitus susceptibility gene, is associated with the regulation of pancreatic β-cell mass. Kanno A, Masuda K, Asahara S, Kimura M, Matsuda T, Kasuga M, Ogawa W, Seino S, Kido Y. 75th Scientific Session of American Diabetes Association. 2015

24. The role of casein kinase 2 in ER stress associated pancreatic β cell failure. Matsuura Y, Matsuda T, Takai T, Inoue K, Suzuki E, Asahara S, Koyanagi-Kimura M, Kanno A, Kido Y. 8th AASD Scientific Meeting. 2016

25. Analysis of Pathogenic Mechanism by Susceptibility Genes of T2DM Using Human iPS Cells. Shimono N, Asahara S, Kido Y. 77th Scientific Sessions of American Diabetes Association. 2017

26. Effect of removal of glucotoxicity by SGLT2 inhibitor dapagliflozin on the gene expression in pancreatic beta cells. Asahara S, Ohashi Y, Kido Y. International Diabetes Federation2017. 2017

27. Identification of the regulatory mechanism of mTORC1 signaling activity in pancreatic ß-cells in GCN2 knockout mice. Kudo M, Kanno A, Asahara S, Kido Y. 79th Scientific Sessions of American Diabetes Association. 2019
